Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9551+0.0251 (+2.70%)
At close: 04:00PM EDT
0.9551 0.00 (0.00%)
After hours: 07:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9300
Open0.9149
Bid0.9550 x 800
Ask0.9551 x 800
Day's Range0.9002 - 0.9786
52 Week Range0.6500 - 5.6400
Volume571,045
Avg. Volume872,506
Market Cap59.166M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-1.5740
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.60
  • Zacks

    Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates

    Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

    CAMBRIDGE, Mass., August 09, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.

  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., August 04, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 31,000 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Advertisement
Advertisement